TP ICAP Group PLC (TCAP) — Investment Research Note

Executive summary

TP ICAP is the world's largest wholesale inter-dealer broker, connecting institutional buyers and sellers across four divisions: Global Broking (~58% of revenue), Energy & Commodities (~20%), Liquidnet agency execution (~15%) and Parameta Solutions OTC data (~8%). Since 2019 the group has grown revenue at a ~5% CAGR, expanded adjusted EBIT margin from ~13% to 15% at H1 2025, dramatically improved cash conversion (61% in 2019 → 124% in 2023), and delivered a record Q1 2026 (£689m, +13% cc) as elevated rate volatility and buoyant energy volumes drove double-digit growth in the two largest divisions 2026-05 Q1 trading update; 2025-08 half-year. The single most important valuation swing factor is the potential US minority listing of Parameta Solutions (subscription data business, 40% EBIT margin, 98% ARR) which the Board is actively assessing — should it proceed and the Group return most proceeds to shareholders as guided, a large latent sum-of-parts discount could be crystallised 2026-08 half-year; 2026-03 final results.

Fair value estimate

Methodology: sum-of-parts on adjusted 2025E divisional EBIT, cross-checked with forward P/E and dividend yield.

Using FY 2024 divisional adjusted EBIT run-rate, adjusted upwards for H1 2025 momentum:

• Broking businesses (GB £205m + E&C £56m + Liquidnet £53m − Corporate £73m ≈ £240m adjusted EBIT) at 8-9x EBIT: £1,920m – £2,160m
• Parameta Solutions (£83m adjusted EBIT, subscription data, growing 5-10%) at 15-20x EBIT: £1,245m – £1,660m (peer data businesses trade 15-25x)
• Less net debt ex-leases (~£300m after H1 2025 refinancing) and adjust for ~£65m cash returned to shareholders since

Fair value range: 320p – 400p per share; implied market cap £2,320m – £2,900m; midpoint ~360p / £2,610m.

Current market cap £2,485m at 326p → absolute upside ~10% to midpoint, range −2% to +23%.

Cross-check: FY 2024 adjusted EPS 31.8p, H1 2025 EPS 17.6p (+9%). FY 2025E EPS ~35p; at current 326p that is ~9.3x forward, in line with UK financials averages. Dividend of 16.8p implies ~5.2% yield.

Sector context

Sector confirmed: Financials / Financial Services. ICB Super-Sector: Financial Services (inter-dealer broker / market infrastructure sub-industry). Quality is broadly in line with sector peers: investment-grade, cash-generative, market-leading positions, but with structural pressure from electronification and dependence on volatility for a large part of the P&L. Leverage (1.6x EBITDA) is lower than typical financials. Growth is above traditional bank/insurer growth but below fintech/exchange peers.

Listed peers: Marex (MRX.L / MRX) — smaller diversified broker growing faster; BGC Group (BGC) — closest US-listed IDB comparator, trades on ~7-9x EPS; Compagnie Financière Tradition (CFT.SW) — European IDB peer.

Investment thesis

• Parameta value unlock is a live catalyst. Board is actively progressing options including US minority listing of the world's #1 OTC data business (~70% market share of inter-dealer OTC data) with intention to return most proceeds to shareholders and retain majority ownership 2025-08 half-year; 2026-03 final results. On our numbers Parameta alone could be worth ~50% of current market cap — a partial monetisation would leave the remaining broking businesses at a very low implied multiple.
• Cash generation supports material shareholder returns. Group is running its fifth £30m buyback in 24 months (£150m total), dividend up 8% at interim, and management guides "in excess of £200m" of surplus cash across 2026-2027 2025-08 half-year. At the current price this ~£100m/year of returns is ~4% of market cap, on top of the ~5% dividend yield.
• Structural tailwind from elevated rates and market volatility. Global Broking (58% of revenue, highest-margin division) is a direct beneficiary of the end of the zero-rate era. Q1 2026 delivered record group revenue with GB +15% cc, and management remains "comfortable with the outlook" 2026-05 Q1 trading update. Rates alone drove £327m of H1 2025 revenue, +14% cc 2025-08 half-year.

Key risks

• Liquidnet integration remains value-destructive so far. Cumulative £76m goodwill/customer-relationship impairments taken in 2023 on the Liquidnet cash equities acquisition; the division only returned to modest EBIT growth in 2024/2025 after multiple restructuring rounds 2024-03 final results. Further asset write-downs are possible if equity block market conditions weaken.
• Legal and regulatory tail is meaningful. Ongoing cum-ex proceedings in Germany (Cologne, Frankfurt), Warburg civil claim (~€237m potential exposure with partial dismissal, TPICAP appealing), Portigon and Liquidnet SEC matters. While partial NEX indemnities exist, timing and quantum are uncertain and cash outflows have exceeded £70m over the period 2025-08 half-year contingent liabilities note.
• E&C revenue softness and structural competition for talent. E&C revenue declined 3% at 9M 2025 (-5% reported) as "competition for broking talent" bit; the division depends heavily on broker recruitment/retention and a talent war can compress margins with little revenue offset 2025-11 Q3 trading update.

Operating leverage

TP ICAP has moderate operating leverage by design. The cost structure is roughly 55% front-office costs (largely variable — broker compensation scales with revenue), ~25% management & support costs (largely fixed) and ~20% depreciation/amortisation + finance costs (fixed). H1 2025 contribution margin was 38.0% on revenue of £1,224m 2025-08 half-year. This means each incremental £1 of revenue generates £0.38 of contribution before support cost absorption; once fixed support costs (£280m/year) are covered, incremental revenue drops through at broadly the contribution margin. Liquidnet is the clearest example of the leverage in action — H1 2025 saw Liquidnet revenue +15% deliver adjusted EBIT +38%. Parameta is the highest-leverage sub-division (98% subscription, 44% contribution margin, 36% EBITDA margin) but is a small share of the total. A 15-20% group revenue beat vs consensus would plausibly deliver ~30-45% operating profit uplift — meaningful but not the multi-bagger leverage seen in software/platform businesses.

Value-trap signals

• Consistent gap between reported and adjusted earnings (~30% of adjusted profit stripped out via "significant items") — 2023 significant items were £180m pre-tax; guidance for 2025 is c.£115m — indicating restructuring is now perpetual rather than transient.
• Multi-year track of "one-off" litigation costs (LIBOR, cum-ex, CFTC, SEC) argues these are recurring cost-of-business items, not truly exceptional.
• The Liquidnet acquisition (2021) has needed cumulative £76m of impairments and repeated integration cost programmes; management credibility on M&A is mixed.

Earnings vs. expectations

Across the covered period the pattern is broadly meets/beats, with no profit warnings. Guidance style is qualitative ("Board remains comfortable with market expectations") but management has consistently either met or narrowly beat it:

• FY 2024: revenue +5% cc, adjusted EBIT +12% cc — delivered "at or above" 2023 CMD targets on most metrics
• FY 2023: adjusted EBIT £300m record — exceeded prior year and CMD contribution margin targets for GB and E&C
• H1 2025 and Q1 2026 both delivered records against comparators
• 2020 CMD targets were revised downward at FY 2022 (Group EBIT margin from 18% to 14%) reflecting Covid impact and Liquidnet challenges — one meaningful downgrade in the period Overall: more beats than misses in recent quarters, though the 2022 CMD reset is a marker of realism catching up with initial ambition.

Conviction

Conviction: 3 (moderate).

Anchoring the conviction: (a) disclosure is thorough and consistent, with detailed divisional adjusted metrics year-on-year; (b) valuation triangulates across P/E, dividend yield and sum-of-parts at broadly similar ranges (315-400p); (c) the recent trading momentum is well-documented across quarterly updates.

Limiting the conviction: (a) the sum-of-parts valuation hinges materially on the Parameta minority listing outcome and multiple, both of which are uncertain — a no-listing scenario would probably compress fair value to the 300-330p range; (b) the persistent gap between adjusted and reported earnings and the ongoing legal contingencies introduce genuine range around "true" earning power.

Driver scoring rationale

• AI beneficiary (30): Fundamentally a broker/data business, not an AI infrastructure play. Some indirect angle via Parameta's proprietary OTC data (potentially valuable for AI training/pricing models), AWS partnership on Fusion, and rollout of Amazon Q Developer internally, but there is no AI-driven revenue line. Would only be a real AI receiver if Parameta commercialises its data specifically to AI-training buyers.
• Operating leverage (50): Moderate — see paragraph above. High variable broker comp caps the leverage, though Parameta and Liquidnet show pockets of stronger dropthrough.
• Cyclicality (55): Financials sector, volatility-dependent revenue in GB and E&C; Parameta subscription base provides some ballast; overall moderately cyclical.
• Moat (55): #1 in inter-dealer OTC broking and OTC data (~70% share), 60+ offices, 2,500+ brokers, deep buy/sell-side relationships. Faces electronification pressure and competing IDBs (Marex, BGC, Tradition).
• Leverage (35): 1.6x EBITDA, investment grade, well-refinanced with £750m of staggered sterling notes. Comfortable.
• Earnings quality (55): Cash conversion strong (124-144%), but ~30% of adjusted profit removed as "significant items" year in year out; heavy legal contingencies; multiple restatements over the period.
• Management quality (60): CEO in place since 2018; delivered most 2020 CMD targets; consistent capital returns and dividend growth; Liquidnet acquisition experience mixed but Parameta value-unlock exploration is shareholder-friendly.
• Growth momentum (65): Recent quarters have been strong (Q1 2026 record, H1 2025 +9%, 9M 2025 +7%). Rates and E&C tailwinds sustaining.
• Earnings surprise trend (60): Consistently at-or-above guidance across period; more beats than misses; no profit warnings.

Overall score rationale

Score 380 / 1000 — low-to-partial fit for this investor's strategy. TP ICAP scores poorly on the ~35%-weighted AI-beneficiary pillar (it is a broker, not an AI receiver), moderately on operating leverage, well on valuation discipline (trading at ~9x forward EPS with 5% yield and a genuine Parameta catalyst), and well on downside protection (investment grade, dividend, market leadership). It is a "reasonable fundamental buy at fair price" rather than a strategy-fit name.